Theory and strategy for Pneumococcal vaccines in the elderly
作者： Ho Namkoong , Makoto Ishii , Yohei Funatsu , Yoshifumi Kimizuka , Kazuma Yagi
DOI: 10.1080/21645515.2015.1075678
关键词:
摘要: Pneumonia is the fourth-leading cause of death globally, and Streptococcus pneumoniae most important causative pathogen. Because incidence pneumococcal diseases likely to increase with aging society, we should determine an optimal strategy for vaccination. While consensus indicates that 23-valent polysaccharide vaccine prevents invasive (IPD), its effects on community-acquired pneumonia (CAP) remain controversial. Recently, a 13-valent conjugate (PCV13) was released. The latest clinical study (CAPiTA study) showed PCV13 reduced vaccine-type CAP IPD. Based these results, Advisory Committee Immunization Practices recommended initial vaccination elderly. Scientific evidence regarding immunosenescence needed more ideal elderly impaired innate adaptive immunity. Continuing research cost effectiveness new strategies considering constantly changing epidemiology also warranted.
elsevier.com
sci-hub.se 参考文章(103)
S. Kularatna, P.R. Wijesinghe, M.R.N. Abeysinghe, K. Karunaratne, L. Ekanayake, Burden of invasive pneumococcal disease (IPD) in Sri-Lanka: Deriving a reasonable measure for vaccine introduction decision making. Vaccine. ,vol. 33, pp. 3122- 3128 ,(2015) , 10.1016/J.VACCINE.2015.04.093
Angel Vila-Corcoles, Olga Ochoa-Gondar, Preventing pneumococcal disease in the elderly: recent advances in vaccines and implications for clinical practice. Drugs & Aging. ,vol. 30, pp. 263- 276 ,(2013) , 10.1007/S40266-013-0060-5
Janne A. Martikainen, Erkki J. Soini, Juha Laine, Heidi Åhman, Ville Postila, Peter Klemets, Economic impact of 13-valent pneumococcal conjugate vaccine in Finnish adults ≥50 years with underlying chronic medical conditions. Journal of Evaluation in Clinical Practice. ,vol. 20, pp. 333- 341 ,(2014) , 10.1111/JEP.12131
Insoo Kang, Myung Sun Hong, Helena Nolasco, Sung Hwan Park, Jin Myung Dan, Jin-Young Choi, Joe Craft, Age-Associated Change in the Frequency of Memory CD4+ T Cells Impairs Long Term CD4+ T Cell Responses to Influenza Vaccine Journal of Immunology. ,vol. 173, pp. 673- 681 ,(2004) , 10.4049/JIMMUNOL.173.1.673
D A Lill-Elghanian, P L Witte, R P Stephan, Development of B cells in aged mice: decline in the ability of pro-B cells to respond to IL-7 but not to other growth factors. Journal of Immunology. ,vol. 158, pp. 1598- 1609 ,(1997)
J. M. Lord, S. K. Butcher, E. Sapey, N. V. Henriquez, A. Sinclair, L. Nayak, H. Chahal, D. O’Mahony, Senescence in innate immune responses: reduced neutrophil phagocytic capacity and CD16 expression in elderly humans. Journal of Leukocyte Biology. ,vol. 70, pp. 881- 886 ,(2001) , 10.1189/JLB.70.6.881
J. Ruiz-Aragón, S. Márquez Peláez, J.M. Molina-Linde, A.M. Grande-Tejada, Safety and immunogenicity of 13-valent pneumococcal conjugate vaccine in infants: A meta-analysis Vaccine. ,vol. 31, pp. 5349- 5358 ,(2013) , 10.1016/J.VACCINE.2013.09.008
Ho Namkoong, Yohei Funatsu, Kazunori Oishi, Yukihiro Akeda, Rika Hiraoka, Kei Takeshita, Takahiro Asami, Kazuma Yagi, Yoshifumi Kimizuka, Makoto Ishii, Sadatomo Tasaka, Yukio Suzuki, Satoshi Iwata, Tomoko Betsuyaku, Naoki Hasegawa, Comparison of the immunogenicity and safety of polysaccharide and protein-conjugated pneumococcal vaccines among the elderly aged 80 years or older in Japan: an open-labeled randomized study. Vaccine. ,vol. 33, pp. 327- 332 ,(2015) , 10.1016/J.VACCINE.2014.11.023
N. CHIBA, M. MOROZUMI, K. SUNAOSHI, S. TAKAHASHI, M. TAKANO, T. KOMORI, K. SUNAKAWA, K. UBUKATA, Serotype and antibiotic resistance of isolates from patients with invasive pneumococcal disease in Japan. Epidemiology and Infection. ,vol. 138, pp. 61- 68 ,(2010) , 10.1017/S0950268809990239
Steven Black, The role of health economic analyses in vaccine decision making. Vaccine. ,vol. 31, pp. 6046- 6049 ,(2013) , 10.1016/J.VACCINE.2013.08.008